PTCT PTC Therapeutics, Inc.Stock Price & Overview
$28.57
Charts
Quant Ranking
PTCT Analysis
PTCT News
Latest Headlines
Ratings Summary
People Also Follow
Similar to PTCT
ETFs Holding PTCT
PTCT Company Profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
PTCT Revenue
PTCT Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
PTCT Ownership
PTCT Peers
Risk
Technicals
PTCT Transcripts
Investor Presentations
PTCT SEC Filings
Press Releases
PTCT Income Statement
PTCT Balance Sheet
PTCT Cash Flow Statement
PTCT Long Term Solvency
Discover More
You may be interested in: